ArticleAntimicrobial agents and chemotherapy2002
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity.Infection and immunity · 2016Article
- Mycoplasma genitalium: should we treat and how?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Article
- Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.Antimicrobial agents and chemotherapy · 2005Article
- In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.Antimicrobial agents and chemotherapy · 2004Article
- Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.Antimicrobial agents and chemotherapy · 2003Article
- In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.Antimicrobial agents and chemotherapy · 2003Article
- In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.Antimicrobial agents and chemotherapy · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.